Colon Cancer Video Channel

Explore the latest insights and summaries from experts in Colon Cancer.

Therapeutic Agents

20:34

Yale Cancer Center

Personalized Treatment for Metastatic CRC

FEATURING Michael Cecchini
  • 47 views
  • April 26, 2024
  • 1
13:23

Hagop Youssoufian

Metastatic Colon Cancer: New Drugs for New Vessels

  • 131 views
  • May 9, 2024
  • 2
08:19

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Randomized ARC-9 Study to Evaluate Etrumadenant-Based Combinations in Previously-Treated mCRC"

FEATURING Zev A. Wainberg
  • 69 views
  • June 10, 2024
  • 1
06:51

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "PanaMa Trial - FU/FA Maintenance Therapy With or Without Panitumumab in RAS Wild-Type mCRC"

FEATURING Dominik Modest
  • 308 views
  • June 10, 2024
  • 1
05:06

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "CheckMate 8HW Trial - Nivo + Ipi With Chemo in 1L MSI-H/dMMR mCRC"

FEATURING Heinz-Josef Lenz
  • 71 views
  • June 10, 2024
  • 1
06:50

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "FIH Trial of M9140, an Anti-CEACAM5 ADC With Exatecan Payload, in Pts With mCRC"

FEATURING Scott Kopetz
  • 81 views
  • June 12, 2024
  • 1
04:14

Insights from 2024 ASCO® GI Annual Meeting

ASCO® 2024 Insights: "FRESCO-2 Trial - Q-TWiST Analysis of Fruquintinib + Best Supportive Care Compared With Placebo + Best Supportive Care in mCRC"

FEATURING Sebastian Stintzing
  • 39 views
  • June 12, 2024
30:26

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NEOPRISM-CRC Trial - Neoadjuvant Pembro Stratified to TMB for High-Risk Stage 2 or 3 dMMR/MSI-High CRC"

FEATURING Kai-Keen Shiu
  • 90 views
  • June 12, 2024
  • 1
12:35

Dana-Farber Cancer Institute

Immunotherapy for Lynch Syndrome Cancers

FEATURING Leah Biller
  • 67 views
  • July 1, 2024
21:30

Total Health

Liver Directed Therapies and Hepatic Arterial Infusion Pumps

FEATURING Cindy O'Bryant
  • 112 views
  • July 2, 2024
03:33

Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: CodeBreaK 300 - Patient-Reported Tolerability of Sotorasib & Panitumumab vs. Trifluridine/Tipiracil or Regorafenib in mCRC

FEATURING Julien Taieb
  • 203 views
  • July 3, 2024
  • 1
07:58

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Analyses of TTX-080, a First-in-Class HLA-G Antagonist, in Combination With Cetuximab in Patients With mCRC and HNSCC"

FEATURING Susanna Ulahannan
  • 48 views
  • July 3, 2024
12:29

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

FEATURING Cathy Eng
  • 208 views
  • July 9, 2024
  • 2
07:59

Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: DEEPER Trial - m-FOLFOXIRI + Cetuximab vs. Bevacizumab in Right-Sided/BRAF Mutant mCRC

FEATURING Yu Sunakawa
  • 131 views
  • July 11, 2024
  • 1
VIDEO

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Botensilimab + Balstilimab in Microsatellite Stable mCRC - Assessing Efficacy in Non-Liver Metastatic Sites"

FEATURING Andrea Bullock
  • 127 views
  • August 1, 2024
37:16

University of Miami Sylvester Comprehensive Cancer Center

The TAPUR Study: Evaluating Targeted Therapies Based on Genetic Alterations in Diverse Cancer Types

FEATURING Richard Schilsky
  • 142 views
  • August 21, 2024
  • 1
03:23

ecancer

ESMO GI 2024 Insights: SOREGATT/PRODIGE 68 - Sequencing TAS-102 and Regorafenib in Patients With mCRC After Two Prior Treatments

FEATURING Michel Ducreux
  • 62 views
  • August 27, 2024
11:25

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: CFT1946, a Novel BRAF V600X Degrader, in Preliminary Results in BRAF V600 Mutant Solid Tumors

FEATURING Maria Vieito
  • 26 views
  • September 20, 2024
18:26

Ibrahim Sahin

Guidance on Incorporating Anti-EGFR Therapy in 1L CRC Practice

  • 143 views
  • September 20, 2024
  • 1
06:20

Ibrahim Sahin

Anti-EGFR Therapy in CRC: How to Manage Toxicities

  • 142 views
  • September 20, 2024
  • 1
14:19

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

FEATURING Howard Hochster
  • 484 views
  • September 23, 2024
  • 5
14:03

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: POD1UM-303/InterAACT 2 - Retifanlimab + C-P in Untreated Inoperable or Metastatic Anal Squamous Cell Carcinoma

FEATURING Sheela Rao
  • 70 views
  • September 27, 2024
  • 1
06:55

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Fruquintinib in Refractory mCRC - Subgroup Analysis of the FRESCO-2 Trial

FEATURING Rocio Garcia-Carbonero
  • 59 views
  • October 1, 2024
24:13

Ibrahim Sahin

Anti-EGFR Therapy in CRC: How to Incorporate Into Practice and Manage Toxicities

  • 27 views
  • October 1, 2024
10:29

Springer Healthcare IME

Targeted Therapy for NTRK Fusion-Positive Cancers

FEATURING Alex Drilon
  • 78 views
  • October 1, 2024
  • 1
13:59

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: EP0031 - Next-Generation RET Inhibitor Correlating Molecular and Clinical Responses in RET-Altered Solid Tumors

FEATURING Elena Garralda
  • 41 views
  • October 11, 2024
  • 1
18:22

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Sequencing CRC Targeted Therapies Based on Biomarkers and Biology

FEATURING Lukas Weiss
  • 65 views
  • November 4, 2024
08:45

Total Health

Latest Data on Immunotherapy for dMMR/MSI-H CRC

FEATURING Axel Grothey
  • 53 views
  • November 10, 2024
  • 1
04:43

Nicholas DeVito

1L Botensilimab + Balstilimab in Stage IV MSS CRC Without Liver Mets: The BB-OpCo Trial

  • 100 views
  • November 13, 2024
  • 2
19:28

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: IMHOTEP Trial - Neo-Adjuvant IO for dMMR/MSI CRC

FEATURING Olivier Dubreuil
  • 36 views
  • November 25, 2024
09:19

Insights from 2024 ASCO® GI Annual Meeting

ASCO® GI 2024 Insights: "LIBRETTO-001 Study - Durable Efficacy of Selpercatinib in Patients With RET Fusion+ Solid Tumors (Focus on GI Tumors)"

FEATURING Vivek Subbiah
  • 45 views
  • March 5, 2024
13:29

Ibrahim Sahin

Treating KRAS-Mutated mCRC

  • 702 views
  • March 8, 2024
  • 2
11:23

Weill Cornell Medicine Oncology & Hematology

ASCO® GI 2024 Insights: "The NEST-1 Trial - Neoadjuvant BOT/BAL in Resectable MMR-Proficient and -Deficient CRC"

FEATURING Pashtoon Kasi
  • 233 views
  • March 8, 2024
  • 2
10:11

Yale Cancer Center

GI Oncology Year in Review: Key mCRC Studies Including CheckMate 8HW & CodeBreaK 300

FEATURING Michael Cecchini
  • 111 views
  • March 11, 2024
  • 1
18:23

Ibrahim Sahin

Treating BRAF-Mutated mCRC

  • 337 views
  • March 15, 2024
  • 1
18:02

Ibrahim Sahin

Treating HER2-Amplified mCRC

  • 373 views
  • March 22, 2024
  • 3
30:57

Integrity CE

Vaccines as Cancer Therapy: Current Status in GI Tumors

FEATURING Neeha Zaidi
  • 50 views
  • March 27, 2024
13:51

Dana-Farber Cancer Institute

Overview of Dosing and Toxicity of Radiation Therapy in CRC

FEATURING Miranda Lam
  • 33 views
  • April 19, 2024
16:47

Dana-Farber Cancer Institute

Using Aspirin and Vaccines for Lynch Syndrome Cancer Management

FEATURING Ramona Lim
  • 39 views
  • July 3, 2024
12:35

Eric Miller

ERASur: A Ph3 Study of Total Ablative Therapy for Limited mCRC (A022101/NRG-GI009)

FEATURING Paul Romesser
  • 66 views
  • September 9, 2024
  • 1